SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Here’s What Happened

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) gapped down prior to trading on Friday . The stock had previously closed at $15.21, but opened at $14.77. SELLAS Life Sciences Group shares last traded at $14.38, with a volume of 1,176,568 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on SLS shares. Alliance Global Partners reissued a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Stock Performance

The firm’s fifty day simple moving average is $12.37 and its 200 day simple moving average is $8.05. The stock has a market capitalization of $2.78 billion, a P/E ratio of -65.52 and a beta of 2.48.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.01).

Hedge Funds Weigh In On SELLAS Life Sciences Group

Institutional investors have recently modified their holdings of the business. Nykredit A S acquired a new stake in SELLAS Life Sciences Group in the second quarter valued at about $27,000. Larson Financial Group LLC bought a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth about $26,000. California State Teachers Retirement System boosted its stake in shares of SELLAS Life Sciences Group by 22.4% in the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after purchasing an additional 1,709 shares in the last quarter. Beacon Pointe Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group during the 4th quarter valued at approximately $38,000. Finally, Concurrent Investment Advisors LLC bought a new stake in shares of SELLAS Life Sciences Group during the 4th quarter valued at approximately $38,000. Institutional investors and hedge funds own 17.38% of the company’s stock.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.